A big part of the success of a drug in India has to do with the cost, which is often less than half the world average.
That has made some pharmaceuticals very profitable in India, but also the pharma industry in general.
The company that’s been dominating the sector for the past two decades has been adare pharmaceutical, which started in 2002 and has grown to become the largest pharmaceutical company in India with revenue of $12.5 billion in 2017.
But it has struggled to keep pace with the rising prices of the Indian market.
Adare has been in India since 1993 and was one of the first companies to develop the first-line of treatment for cancer.
It is still the largest supplier of chemotherapy drugs in India.
It has grown from a small company to the largest, with revenues of $3 billion in 2016.
The new pharma giant, Zynerba Pharmaceuticals, also is an early-stage company, having started with just $300 million in revenue in 2013.
The stock has been soaring in the last couple of years, with its stock up 20 per cent this year.
The company’s CEO, Sudhir Kumar, said in a recent interview with NDTV that the pharmacare sector in India was growing at about a 20 per,cent compounded annual growth rate, which was about 2.2 per cent in 2017, but that has been trending down in the past couple of quarters.
He said that there is an oversupply of the drugs in the country.
“We will continue to see demand, and we will make the products that will be available at the lowest price that we can,” Kumar said.
Adare’s focus on cancer therapy has brought in a number of other pharma companies.
Vikram Pandit, co-founder of Medtech, a healthcare technology company, said that the growth in cancer therapy in India is driven by an underutilization of chemotherapy in the developing world.
He added that the market has also started to grow and be a lot more attractive for drugmakers.
“India is the second largest producer of cancer medicines in the world, after China,” Pandit said.
“When it comes to drugs, there is a very clear demand in India for this.”
Pandit said that Adare was looking at ways to expand its business in India and added that it was a challenging time for the pharmacist.
“In the last two years, the cost of chemotherapy has increased by 10 to 15 per cent,” he said.
“That is a big challenge for our pharmacy.
The pharmacist needs to make sure that there are enough patients to fill up his prescriptions.
Pandits pharma business has grown as well.
“We have grown our business from one-third of what it was in 2016 to one-fourth of what we are today,” he added.
He added that Adand is looking to grow its business even further.
With the introduction of a new drug, there are several companies looking to do it as well, he said, adding that the Indian pharmacist is still an important role model for many pharma CEOs.
I am very proud of Adare.
I feel very privileged.
It will be a long road for me to see how far we can go in the future, Pandit told NDTV.
When asked if Adare had ever considered taking on other pharmas, Pandits reply was, “We are a company of a single minded focus.
We have the best doctors in India working on our behalf.”
Adand’s focus has been on cancer treatment in India because of its experience and expertise.
Its patients have included Prime Minister Narendra Modi, former prime minister Atal Bihari Vajpayee and former president Pranab Mukherjee.
‘The market has started to rise’ Pandita said that he feels that India is on a very good path.”
There is a market here that has started rising. “
We have seen very good results from our medicines.
There is a market here that has started rising.
There are so many people who are willing to give up and take up their medicine.
It’s very exciting.”
I believe India is very bright.
I believe we are a very smart country, Pandita added.